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Olive oil polar lipid (OOPL) extract has been reported to inhibit atherosclerosis development on rabbits. Olive pomace polar
lipid (PPL) extract inhibits PAF activity in vitro and the most potent antagonist has been identiﬁed as a glycerylether-sn-2-acetyl
glycolipid with common structural characteristics with the respective potent antagonist of OOPL. The aim of this study was to
investigate the eﬀect of PPL on early atherosclerosis development on rabbits and to compare it with the antiatherosclerotic eﬀect
of OOPL. OOPL and PPL inhibition potency, towards both PAF action and PAF binding, was tested in vitro on washed rabbit
platelets. Consequently, rabbits were divided into three groups (A, B, and C). All groups were fed atherogenic diet for 22 days.
Atherogenic diets in groups B and C were enriched with OOPL and PPL, respectively. At the end of the experimental time, rabbits
wereeuthanizedandaorticsampleswereexaminedhistopathologically.OOPLandPPLinhibitedPAF-inducedaggregation,aswell
as speciﬁc PAF binding, with PPL being more potent. Free and bound PAF levels and PAF-AH activity were signiﬁcantly elevated
at the end of the experimental time. Plasma total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides levels were also
found increased. Groups B and C exhibited signiﬁcantly increased values of EC50 compared to group A. Histopathological exam-
ination revealed that the development of early atherosclerosis lesions in groups B and C were signiﬁcantly inhibited compared
to group A. Signiﬁcant diﬀerences were noted in the early atherosclerosis lesions between groups B and C, thus indicating that
PPL exhibit its anti-atherosclerotic activity by blocking PAF receptor. Speciﬁc PAF antagonists with similar in vitro and in vivo
bioactivity to those that have been previously reported in OOPL exist in PPL.
Copyright © 2007 Nektaria Tsantila et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Coronaryheartdisease(CHD)isthemajorsourceofmortal-
ity in theWestern World. Although it wasbelieved thatthis is
principally a problem of the developed world, new evidence,
provided by the World Health Organization, shows that car-
diovascular disease will become a major problem in develop-
ing countries as well, unless they stop acquiring Western nu-
tritionalhabits.Heartattackandstrokearetheclinicalresults
of a systemic vascular process widely known as atherosclero-
sis [1]. Atherosclerosis can be described as a systemic vascu-
lar process consisting microscopically of foam cell formation
in the subendothelial space, inevitably leading to fatty streak
and then ﬁbrous plaque formation [2].
The importance of Mediterranean diet on preventing
CHD has been indicated by several studies [3–5]. Olive oil
is the main source of fat in the aforementioned diet, thus
its beneﬁciary eﬀects on health have been widely examined,
both in vitro and in vivo [4–7].
Olive oil is extracted from olive fruits by pressure, thus
resulting into two wastes: olive mill wastewater (OMW) and
olive pomace (P) [8, 9] .O l i v ep o m a c eo rj u s tp o m a c es t i l l
retains a small amount of olive oil and mainly consists of
water, olive skin, olive ﬂesh, and pit fragments; therefore, its2 Mediators of Inﬂammation
major ingredients are sugars (mainly polysaccharides), pro-
teins, fatty acids (oleic acid and other C2–C7 fatty acids),
polyalcohols, polyphenols, and other pigments [9–12]. It is
mainly used for extracting olive pomace oil (secondary value
oil) [12, 13]; however, it can be used as a fuel as well [14].
According to our theory, platelet activating factor (PAF)
is implicated in atherogenesis [2] and this is also supported
by other researchers [15–18]. The increase of PAF levels and
activity in blood, which occurs both in pathological inﬂam-
matory conditions and during oxidative stress through LDL
and membrane phospholipid oxidation, is believed to be of
crucial importance for the initiation of atherosclerosis. PAF
activity can be controlled either by PAF-AH or by PAF an-
tagonists derived either from food or produced endogenous.
Absence of such antagonists can result to uncontrolled PAF
activity [2]. Such PAF antagonists have been isolated from
various food stuﬀs like yogurt [19], honey [20], wine [21–
23], ﬁsh [24, 25], and olive oil [4, 26], which constitute food
stuﬀs of the Mediterranean diet, thus enhancing our under-
standing of this diet’s beneﬁcial eﬀects on health.
Our group has previously reported the inhibitory eﬀect
of olive oil on experimental atherosclerosis induction in rab-
bits. It was, also, demonstrated that this inhibitory eﬀect is
mainly attributed to OOPL, mainly containing PAF antago-
nists, rather than to olive oil neutral lipids (OONLs), mainly
containing oleic acid and antioxidants [27].
Since, on one hand, a percentage of olive oil is still re-
tained in olive pomace [12] and on the other hand olive po-
mace, as a waste of olive oil industry, has low interest value,
the existence of PAF antagonists in olive pomace, could con-
tribute to increase its biological value. The existence of PAF
antagonists in olive pomace polar lipid (PPL) extract has al-
ready been reported and the bioactive compound has been
chemically characterized as a glycerylether-sn-2-acetyl gly-
colipid sharing structural features with the respective one
of OOPL [28]. The aim of this study is to examine in vivo
theantithromboticandantiatheroscleroticactivityofPPLon
cholesterol fed rabbits and to compare it with the eﬀect of
OOPL.
2. MATERIALS AND METHODS
2.1. Materials
Solvents of analytical grade and for high-performance
liquid chromatography (HPLC) and gas chromatography
(GC) analyses, as well as silicic acid, 35–70 meshes,
ASTM 7733 for column chromatography, were supplied
from Merck (Darmstadt, Germany). Bovine serum al-
bumin (BSA), PAF (1-O-hexadecyl-2-acetyl-sn-glycero-3-
phosphocholine), lipid standards for HPLC and GC, tri-
chloroacetic acid (TCA), cholesterol (∼95% (GC), equiv-
alent to USP/NF), naphthalene (scintillation grade), and
histopaque −1077 were obtained from Sigma (St. Louis,
Mont, USA). [3H]-acetyl PAF (10Ci/mmol) (NET 910) was
purchased from NEN (Dupont, Boston, Mass, USA). 2,5-
diphenyloxazole (PPO) and 1,4-bis(5-phenyl-2-oxazolyl)
benzene (POPOP) were purchased from BDH Chemicals
(Dorset, England). Scintillation liquid cocktail (dioxane
base) was prepared by diluting 7g PPO, 0.3g POPOP, and
100g napthalene in 200mL H2O and then transferred to
1L of dioxane. Tris buﬀer, pH 7.4, contained 50mM Tris.
Theanticoagulantsolutioncontained0.065Mcitricacidand
0.085M sodium citrate. Virgin olive oil of Koroneiki variety
extracted by pressure and its respective olive pomace came
from Kalamata, Greece.
2.2. Methods
2.2.1. Modiﬁedcountercurrentdistribution
Olive oil and pomace were subjected to a modiﬁed counter
current distribution [4]. According to this method, the
ethanol phase at the end yields 96% of the polar lipids as
evaluated with [3H]-PAF, whereas the combined petroleum
ether phases contain the neutral lipid class. This modiﬁed
counter current distribution is normally applied in vegetable
oils [4, 29]. Brieﬂy, every 100mL of olive oil were placed
in a separatory funnel and diluted in 400mL of petroleum
ether (PE) solvent, thus constituting the initial total volume
of 500mL. This solution was then mixed with 100mL of
ethanol 87% solvent. After 5 minutes, the two phases were
separated and a new amount of 100mL ethanol solvent was
addedintheequilibratedupperphaseofPEextract,followed
by the equilibration and separation of the two phases. The
whole procedure was repeated three times totally, thus ob-
taining at the end the OOPL in ethanol extracts of ﬁnal vol-
ume 300mL.
A modiﬁed extraction (Figure 1) of the aforementioned
extraction procedure was applied on olive pomace. Brieﬂy,
for every 100g of olive pomace, 250mL of PE solvent were
added. After 5 minutes in stirring, the liquid is separated
from olive pomace through Buchner ﬁltering. The proce-
dure was repeated once more in the remaining olive po-
mace thus giving 500mL of PE extract in total, which were
placed in a funnel containing 250mL of ethanol solvent. The
two phases were equilibrated and then separated. In the re-
maining residue of olive pomace, 250mL of ethanol solvent
were added twice and after 5 minutes in stirring, both liquids
were removed through Buchner ﬁltering. Ethanol extracts
(500mL) were then placed in a funnel containing 250mL of
PE solvent and the two phases were separated after equilibra-
tion.Allethanolphases,of750mLtotalvolume,werepooled
together, thus consisting the polar lipid extract of olive po-
mace (PPL), while all PE phases, also 750mL total volume,
consisted the neutral lipid extract, which was not further
used.
The evaluation of the above method concerning the re-
covery of polar lipids from olive pomace was performed with
[3H]-PAF.
Petroleum ether (b.p. 40–70◦C) and ethanol 87% sol-
vents were preequilibrated with each other, prior use in ex-
traction procedures.
2.2.2. Preparationofwashedrabbitplatelets
Washed rabbit platelets were prepared as previously de-
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Figure 1: Schematic representation of polar lipid extraction from olive pomace, abbreviated as PPL in the text. PNL: pomace neutral lipids.
2.2.3. Biologicalassayonwashedrabbitplatelets
PAF was dissolved in 2.5mg of BSA per 1mL of saline.
The examined samples were dissolved in absolute ethanol
and BSA 2.5mg/mL saline was added to give a ratio of
ethanol/BSA 1/19. The platelet aggregation induced by PAF
(2.5 × 10
−11 M, ﬁnal concentration) was measured as PAF-
induced aggregation, in washed rabbit platelets, before (con-
sidered as 0% inhibition) and after the addition of various
concentrations of the examined sample as previously de-
scribed [30]. Consequently, the plot of percent inhibition
(ranging from 0 to 100%) versus diﬀerent concentrations of
the sample is linear. From this curve, the concentration of
the sample that inhibited 50% PAF-induced aggregation was
calculated, and this value was deﬁned as IC50.B u ﬀer control
data were performed with 2.5mg of BSA per 1mL saline and
the results were appropriately corrected. In addition, vari-
ousconcentrationsofeachexaminedsamplewereaddedinto
the aggregometer cuvette. According to cross-desensitization
experiments that were performed, platelets were desensi-
tized by the addition of the examined lipid at a concentra-
tion that caused reversible aggregation. Second stimulation
with PAF was performed immediately after complete dis-
aggregation. The study was performed using a Chronolog
aggregometer (model 400) (Havertown, Pa, USA) coupled
to a Chronolog recorder at 37◦C with constant stirring at
1200rpm.
2.2.4. [3H]-PAFbindingtowashedrabbitplatelets
The experiments involving the speciﬁc binding of [3H]-
PAF to washed rabbit platelets and its inhibition by OOPL
and PPL were performed as previously described with some
modiﬁcations [31]. Brieﬂy, [3H]-PAF (1nM), PAF (1μM),
OOPL, and PPL were diluted in absolute ethanol, and BSA
10mg/mL in Tg-Ca2+ buﬀe rp H7 . 2w a sa d d e dt og i v ea
ratio of ethanol/BSA 1/19. Incubations were carried out in
a total 0.5mL volume. In 360μL, Tg buﬀer pH 7.2 con-
tained CaCl2 1.72mM, [3H]-PAF (1nM) in the presence or
absence of either PAF (1μM), OOPL, or PPL were added
and the volume was adjusted in 460μLw i t hB S A1 0m g / m L
in Tg-Ca2+ buﬀer pH 7.2. Then, 40μL of washed rabbit
platelets (1 × 108 platelets) in Tg buﬀer pH 6.2 were added
to start the incubation time. Double incubations were car-
ried out at 22◦C for 4 minutes, a time period where [3H]-
PAF degradation was calculated to be less than 1%. Ter-
mination was performed with the addition of 0.7mL ice-
cold Tg-Ca2+ buﬀer pH 7.2, followed by rapid centrifuga-
tion at 11500 × gf o r2m i n u t e sa t4 ◦C. The speciﬁc PAF
antagonist, BN 52021, was used as a reference compound.
The radioactivity was measured by scintillation counting on
a 1209 Rackbeta liquid scintillation counter from Pharma-
cia (Wallac, Finland). Nonspeciﬁc binding was deﬁned as
the total binding measured in the presence of excess un-
labelled PAF (1μM) and speciﬁc binding was deﬁned as
the diﬀerence between total binding and nonspeciﬁc bind-
ing. The percent inhibition was expressed as %I = (to-
tal binding − total binding with tested compound)/speciﬁc
binding ×100. The IC50 value was deﬁned as the con-
centration of inhibitor required obtaining 50% inhibition
of the PAF speciﬁc binding. Scatchard analysis was per-
formed with GraphPad Prism software (San Diego, Calif,
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2.2.5. Chemicaldeterminations
Phosphorus determination was carried out according to
Bartlett[32].Sugardeterminationwascarriedoutasreferred
by Galanos and Kapoulas [33]. Phenol content determina-
tion was performed using a modiﬁed method of Singleton
and Rossi [34]. Brieﬂy, samples were dried under a stream
of nitrogen and dissolved in 3.5mL of water. An amount of
0.1mL Folin-Ciocalteu reagent was added, followed after 3
minutes by addition of 0.4mL of 35% aqueous Na2CO3.T h e
reaction mixture was kept for 1 hour, and the intensity of the
blue color was measured at 725nm. Standards of gallic acid
were prepared similarly. Ester determination was carried out
according to the method of Renkonen [35].
2.2.6. Fattyacidsanalysis
GC analysis was carried out on a Shimadzu model GC-17A
gas chromatograph (Kyoto, Japan), using an Agilent J & W
DB-23capillarycolumn(60m ×0.25mm,i.e.,0.25μm)pur-
chased by Agilent Technologies (Santa Clara, Calif, USA).
Fatty acids contained in both polar lipid extracts were
quantiﬁed by GC analysis. Both samples were dried under
a stream of nitrogen and then diluted in 1mL of hexane.
Methyl-esteriﬁcation was performed by the addition of 4mL
of KOH 0.5N in methanol/water (90/10) at room tempera-
turefor5minutesundercontinuousvortexing.Afterthatthe
solution was neutralized by the addition of HCl 6N and 2mL
of H2O were added and the fatty acid methylesters were ex-
tracted twice by 2mL hexane each time. Moisture from the
hexane extract was removed using Na2SO4.
Oven thermal program started at 120◦C and remained at
this temperature for 5 minutes, then rose at 180◦C within 6
minutes, followed by a temperature increase at 220◦C within
2 minutes. The temperature remained at 220◦C for 25 min-
utes. Inlet and detector temperatures were 220◦C and 230◦C,
respectively [36].
2.2.7. Animalhandlingandtreatment
EighteenhealthymaleNewZealandrabbitsofspeciﬁcweight
and age were purchased from a commercial breeder and were
individuallyhousedinatomicstainlesssteelcagesinconstant
conditionsoftemperature(19+1◦C),relativemoisture(55+
5%), and air conditioning (12 full changes of air per 1 hour).
The light/darkness ratio was 12 hour/12 hour. Rabbits were
acclimatizedfor5daysbeforethebeginningofthestudy.Liv-
ing conditions and animal handling were according to the
European Regulation 609/86. The local veterinary authori-
ties and animal ethics committee approved the study.
Rabbits were randomly divided into three groups of six
animals each and were given speciﬁc diet for 22 days. Group
A was given atherogenic diet, while groups B and C were
given atherogenic diet enriched with OOPL (0.16% w/w)
and PPL (0.13% w/w), respectively. Their food was prepared
freshly every three days before consumption.
On the 22nd day, rabbits were given xylazine (Rompun,
Bayer, Leverkusen, Germany) 5mg/Kg body weight and
cetamine (Fort Dodge Laboratories Inc., Fort Dodge, Iowa,
USA) 25mg/Kg body weight intramuscularly. Rabbits fell
unconscious and soon afterwards euthanasia took place by
injectingPentothal(HospitalProductsDivision,AbbottLab-
oratories Abbott Park, Ill, USA) 20mg/Kg body weight, in-
travenously. Through a median longitudinal incision, the
thoracic and peritoneal cavities were opened and the aorta
was dissected from the aortic valve down to the aortic bifur-
cation.
2.2.8. Biochemicalmeasurements
At the beginning (0 days) and at the end of the experimental
time (22 days), blood was collected from all rabbits through
themaineararteryandwasplacedinpolyethylenetubescon-
taining anticoagulant with a ratio of blood/anticoagulant 9 :
1 (v/v).
2.2.8.1.PRPaggregation
Platelet-rich plasma (PRP) was obtained by centrifugation
of blood samples at 562 × g for 13 minutes, while platelet-
poor plasma (PPP) was obtained by further centrifuging
the specimens at 1750 × gf o r2 0m i n u t e s .T h ec e n t r i f u -
gation was performed on Heraeus Labofuge 400R (Hanau,
Germany) at 24◦C. PRP concentration was adjusted to
300000platelets/mL using the respective PPP.
Aliquots of PAF solution in chloroform/methanol (1 : 1
v/v) were evaporated under a stream of nitrogen, and were
redissolved in BSA (0.25% in saline) in order to obtain PAF
solutions with ﬁnal concentrations ranging from 1.0 × 10
−8
to1.0×10
−5 M.Themaximumreversibleortheminimumir-
reversible PAF-induced platelet aggregation was determined
as the 100% aggregation, and then various PAF concentra-
tions were added, so as to achieve aggregations between 20%
and 80%. These PAF-induced aggregations were of linear re-
sponse to the respective PAF concentration; therefore, the
EC50 valuewascalculated.EC50 accountsforthePAFconcen-
tration inducing 50% aggregation. These studies were per-
formed using a Chronolog aggregometer (model 400) cou-
pled to a Chronolog recorder at 37◦C with constant stirring
at 1200rpm [32].
2.2.8.2.DeterminationofPAF-AHactivity
PAF-AH activity was determined as previously described
[37]. Brieﬂy an amount of PAF was dissolved in chloro-
form/methanol (1 : 1; v/v) and mixed with an appropriate
amount of [3H]-acetyl-PAF. The mixture was dried under
a stream of nitrogen and redissolved in BSA (10μg/μLi n
Tris-HCl buﬀer pH 7.4), giving the [3H]-acetyl PAF solution
with a ﬁnal concentration of 800μMa n das p e c i ﬁ ca c t i v i t y
of 2500cpm/nmol that was used as the substrate of PAF-AH.
PPP was then placed in Tris-HCl 50mM pH 7.4 with a ra-
tio of 3/2000 at 200μL ﬁnal volume. The whole mixture was
incubated at 37◦C for 2 minutes and the reaction was initi-
ated by adding 5μL of 800μM[ 3H]-acetyl PAF/PAF solution
in BSA (10μg/μL in Tris-HCl buﬀer pH 7.4). The reaction
took place at 37◦C for 15 minutes and stopped by bindingNektaria Tsantila et al. 5
the unreacted [3H]-acetyl PAF with an excess of BSA solu-
tion (0.75mg/mL, ﬁnal concentration) following by precipi-
tationwithTCAwithaﬁnalconcentrationof9.6%(v/v).The
mixture was placed in ice bath for 15 minutes and then was
centrifuged at 16,000 × gf o r5m i n u t e s ,a t4 ◦C. The [3H]-
acetate released from the reaction was measured on a liquid
scintillation counter (1209 Rackbeta, Pharmacia) by placing
0.1mL of the suspension liquid into 5.0mL of scintillation
liquid cocktail (dioxane base). Blank assay was performed
with no added plasma. The enzyme activity was expressed
as nmol of PAF degraded per minute per μL plasma.
2.2.8.3.DeterminationofPAFlevelsinrabbitblood
Determination of free and bound PAF levels was carried out
according to Demopoulos et al. [38]. Brieﬂy, 5mL of blood
was collected into glass centrifuge tubes containing 20mL of
cold absolute ethanol. The whole is centrifuged at 280 × g
for 20 minutes, at 4◦C. The supernatant liquid (containing
free PAF levels) was then separated from the cellular pellet
(bound PAF levels) and both samples were subjected to ex-
traction according to the Bligh-Dyer method [39]. The total
lipid fraction from both samples was then further separated
into lipid classes using glass column liquid chromatography
(20cm × 1mm i.d.). The lipid class containing the polar
lipid class (including PAF) was then puriﬁed through HPLC
using a cation exchange column, SCX Partisil 10μm2 5×
4.6cmi.d.purchasedbyWhatman(Maidstone,UK)atroom
temperature, where PAF was collected at approximately 30
minutes [40]. The exact PAF concentration in the specimen
was then measured through biological assay on washed rab-
bit platelets, where the induced aggregation versus known
synthetic PAF concentrations is linear [30]. The analysis was
performed on a Hewlett-Packard series 1100 (Avondale, PA,
USA),equippedwitha100μLloopRheodyne(i7725)injec-
tor.An1100HPUVspectrometerwasusedasdetectorat208
nm. The spectrometer was connected to a Hewlett-Packard
(Avondale, PA, USA) model HP-3396A integrator plotter.
A l ln e c e s s a r yc e n t r i f u g a t i o n sw e r ep e r f o r m e do nH e r a e u s
Labofuge 400R (Hanau, Germany).
2.2.8.4.Lipidproﬁle
Plasma total cholesterol (TC), LDL cholesterol (LDL-C),
HDL cholesterol (HDL-C), and triglyceride (TG) con-
centrations were measured by standard commercial enzy-
matic methods (bioMerieux, Lyon, France) using a parallel-
multichannel analyzer (Type 7170A, Hitachi, Tokyo, Japan).
2.2.9. Histopathologicalexamination
Thoracic aorta specimens were ﬁxed in 10% buﬀered
formaldehyde solution, sectioned and embedded in paraﬃn
waxusingconventionaltechniques.Forthehistopathological
examination 5μm thickness tissue slide sections were then
cut, transferred on slides and stained with haematoxylin and
eosin (H-E).
2.2.10. Atherosclerosisevaluation
Conventional measurements of early atherosclerosis lesions
in the histopathological tissue sections of resected aortas
were performed, using an automated image analysis system.
The apparatus comprised a Sony-Exwave HAD Color Video
Camera (Sony Corporation, Japan), ﬁtted to a Zeiss Axiostar
light microscope (Zeiss, Germany), a host computer (Pen-
tium 90 MHz, 32 MB RAM)and a Sigmascan version 2.0 im-
age analysis software (Jandel Scientiﬁc, Erkrath, Germany).
Foam cell formation is characteristic of the early atheroscle-
rosis lesions. In the present study, early atherosclerosis le-
s i o n sw e r eo b s e r v e da sf o a mc e l ll a y e r sd e v e l o p e di n s i d et h e
blood vessels. Thickness and surface area of the lesions were
assessed as previously described [7].
2.2.11. Statisticalanalysis
NormalitytestswereappliedusingtheKolmogorov-Smirnov
criterion. Results from ex vivo experiments were expressed
as median (25th percentile-75th percentile). The Mann-
Whitney U-test was performed to assess diﬀerences among
diﬀerent groups. The Wilcoxon sign test was used to assess
diﬀerences in the same group at diﬀerent time intervals. Re-
sults from in vivo experiments concerning food consump-
tion, rabbit weight, and body weight increase in all three
groups as well as IC50 v a l u e sa n dw e r ee x p r e s s e da sm e a n
± standard deviation (sd). The t-test was performed to as-
sess diﬀerences between IC50 values, food consumption, rab-
bit weight, body weight increase, and thickness and surface
of early atherosclerosis lesions among all three groups. Dif-
ferences were considered to be statistically signiﬁcant when
P<. 05. Data were analyzed using a statistical software pack-
age (SPSS for Windows, 10.0.1, 1999, SPSS Inc., Chicago, Ill,
USA).
3. RESULTS
Modiﬁed countercurrentdistribution wasusedasextraction
method in order to obtain the two lipid classes OOPL and
PPL, from olive oil and pomace, respectively. This method
has been successfully used on vegetable oils [4]. In order to
evaluate the method’s suitability concerning the recovery of
PPL, [3H]-PAF was used. Pooled ethanol phases, of 750mL
total volume, yield 97% of polar lipids as evaluated with
[3H]-PAF [28].
Olive oil polar lipids (OOPLs) and pomace polar lipids
(PPLs) derived, using the modiﬁed counter current distribu-
tion, from olive oil and pomace, respectively, were weighted
and subjected to chemical determinations. Chemical deter-
minations for total sugars, esters, and phenolic compounds
were positive, while phosphorus was not detected (Table 1).
These results are in accordance with the ones already re-
ported in our previous work [28]. GC fatty acid analysis
performed on OOPL showed the existence of palmitic (16
: 0), palmitoleic (16 : 1), stearic (18 : 0), oleic (cis 18 : 1),
linoleic (18 : 2), and α-linolenic (18 : 3) fatty acids, whereas
in PPL palmitic(16 : 0), oleic (cis 18 : 1), and α-linolenic
(18 : 3) fatty acids were detected. The results expressed as6 Mediators of Inﬂammation
(%) of the total OOPL and PPL are presented in Table 1.
The above extracts were tested in vitro for inhibition of PAF-
induced platelet aggregation. Both OOPL and PPL exhib-
ited antithrombotic activity. The aforementioned inhibitory
activitywasretainedforawiderangeoftestedamountsrang-
ing from 0.01ng to 1.12μg. The most diluted concentra-
tions of OOPL and PPL that resulted in 50% inhibition of
PAF activity were 1.5(±0.009) × 10−10 M and 1.1(±0.004)
× 10−10 M, respectively, based on sugar determination. Fi-
nal concentrations are given based on sugar determination
sincethebioactivemicroconstituentsfrombothextractshave
been characterized as glycolipids [4, 28]. Statistical analysis
showed that OOPL IC50 value was higher (P<. 05) than PPL
IC50 value.
Consequently, [3H] PAF binding assay on washed rab-
bit platelets was studied in both absence and presence of un-
labelled PAF as well as in the presence of OOPL, PPL, and
BN52021 as a reference compound.
Scatchard analysis of binding data indicates the presence
of two populations of binding sites: one with high aﬃn-
ity (speciﬁc binding) with an equilibrium dissociation con-
stant Kd = 2.75±1.16nM and a maximum number of bind-
ing sites Bmax = 391 ± 112fmol/108 platelets (2355 ± 674
sites per platelet) and another one with low aﬃnity (nonspe-
ciﬁc binding) with an equilibrium dissociation constant Kd
= 8.01 ± 2.47nM and a maximum number of binding sites
Bmax = 739 ± 122fmol/108 platelets (4450 ± 735 sites per
platelet).
OurresultsshowthatOOPLandPPLinhibitspeciﬁcPAF
binding on rabbit platelets. The speciﬁc PAF receptor antag-
onist, BN 52021, inhibited PAF binding on rabbit platelets at
a concentration of 2.3(±0.8) × 10
−7 M. In the same way, the
most diluted concentrations of OOPL and PPL that resulted
in 50% inhibition of PAF binding were 1.5(±0.2) × 10
−7 M
and 0.42(±0.11) × 10
−7 M, respectively, based on sugar de-
termination.
Rabbitweightatthebeginning(0days)andattheend(22
days) of the experiment, as well as the daily food consump-
tion, is presented in Table 2.B o d yw e i g h ti ne a c hg r o u pw a s
signiﬁcantly increased at the end of the experimental time
(P<. 05). No statistical diﬀerence was detected in rabbit
weight among groups in both time intervals. In addition, all
groups consumed equal amounts of food (P>. 05).
At the end of the experimental time plasma TC, HDL-C,
LDL-C levels were signiﬁcantly increased in all rabbits, while
TGlevelsinplasmaweresigniﬁcantlyincreasedonlyingroup
A( Table 3).
Attheendoftheexperimentaltime,EC50 valuesweresig-
niﬁcantly increased only in groups B and C, while in group A
these values were signiﬁcantly decreased, compared to those
of the initial time.
Signiﬁcant diﬀerences were also observed in EC50 values
of groups B and C compared to those of group A (Table 4).
PAF levels, both free and bound, measured in rabbit blood
and plasma PAF-AH activity were signiﬁcantly elevated (P<
.05) at the end of the experimental time (22 days) in all
groups (Table 4).
The present study was focused on the early steps of
atherogenesis, characterized by foam cell formation, where
PAF, as the most active inﬂammatory lipid mediator, is be-
lieved to play critical role. The early atherosclerosis lesions,
whichwereobservedasfoamcelllayersandassessedasthick-
ness and surface area developed inside the blood vessels, are
presented in Table 5.
Representative pictures of the morphometric analysis
performed on the aorta specimens appear in Figure 2,w h e r e
atherosclerosis lesions (foam cell layers) are indicated with
arrows. Statistical analysis on the morphometric assessment
dataconcerningthicknessandsurfaceofearlyatherosclerosis
lesions ingroupsrevealedthatrabbitsconsumedatherogenic
diet enriched in OOPL or PPL (groups B and C, resp.) de-
veloped lower early atherosclerosis lesions than rabbits con-
sumed atherogenic diet only (Group A) (P<. 05). Moreover,
the atherosclerosis lesions in group C were also lower than
those noted in group B (P<. 05).
4. DISCUSSION
Olive oil, over the years, has been the subject of many in
vivo studies, concerning its antiatherosclerotic eﬀect. De la
Cruz et al. reported that virgin olive oil administration to
cholesterol-fed rabbits reduced vascular thrombogenicity of
thesubendothelium,increasedantithromboticactivityinthe
endothelium,anddecreasedfoamcellnuclearcountandper-
centage of the wall occupied by foam cells [7]. Aguilera et al.
showed that olive oil administration on atherosclerotic rab-
bits, although does not regress the phenomenon, is able to
stop further the progression of atherosclerosis process [41].
The beneﬁcial eﬀects of olive oil were initially attributed
to oleic acid and MUFAs, in general, through their action
as antioxidants. Recent studies reported that olive oil anti-
atherosclerotic eﬀect might also be attributed to microcon-
stituents of olive oil, such as phenolic compounds or pheno-
lic glycosides [4, 5, 42].
PAF has been implicated in atherosclerosis [2, 15–18]
whilespeciﬁcPAF-antagonists(BN52021)aswellastheones
extracted from olive oil inhibited atherosclerosis develop-
ment on cholesterol fed rabbits [27, 43].
Inthepresentstudy,suchPAF-antagonistswereextracted
from both olive oil and pomace. The extraction process
yielded 97% of pomace polar lipids as evaluated with [3H]-
PAF that shows the method’s suitability for solid samples.
Total sugar determination showed that both extracts con-
tain equal amount of sugars, expressed as glucose, and for
this reason IC50 values expression was based on this deter-
mination. Phenolic compound determination showed that
PPL contains almost twice the phenolic compound amount
than OOPL. This was of no great surprise, since pomace has
a higher concentration in olive skin and pigments, both rich
in phenolic compounds [9–11], than olive oil. Concerning
fatty acid composition, pomace oil has been reported to have
prettymuchthesamefattyacidcompositionasoliveoil.This
was expected, since pomace retains olive oil, which is further
extracted using hexane, thus producing pomace oil mainly
containingpomacefattyacids[44].Inthepresentstudy,fattyNektaria Tsantila et al. 7
Table 1: Percentage yield, chemical determination, and fatty acid analysis results on OOPL and PPL.
OOPL (n = 3) PPL (n = 3)
Weight (mg/g olive oil) 12.09 ±0.10 —
Weight (mg/g pomace) — 31.45 ±6.68
Yield (% w/w) 1.20 ± 0.01 3.14 ±0.66
Esters (μmol/mg polar lipids) 1.38 ± 0.03 0.50 ±0.01
Sugars expressed as glucose (μmol/mg polar lipids) 0.45 ± 0.01 0.44 ±0.01
Phenolics expressed as gallic acid (μmol/mg polar lipids) 0.030 ± 0.001 0.050 ±0.001
Phosphorus (μmol/mg polar lipids) n.d. n.d.
16 : 0 (mg/100mg polar lipids) 0.125 ± 0.004 0.120 ±0.003
16 : 1 (mg/100mg polar lipids) 0.041 ± 0.001 n.d.
18 : 0 (mg/100mg polar lipids) 0.008 ± 0.004 n.d.
cis 18 : 1 (mg/100mg polar lipids) 1.039 ± 0.022 0.608 ±0.022
18 : 2 (mg/100mg polar lipids) 0.122 ± 0.003 n.d.
18 : 3 (n −3) (mg/100mg polar lipids) 0.094 ± 0.005 0.038 ±0.009
OOPL: olive oil polar lipid; PPL: Pomace Polar Lipids; n.d.: not detected; Values are expressed as mean ± sd.
Table 2: Body weight, daily food consumption and diet composition of experimental groups.
Group A Group B Group C
Diet composition (% w/w) Cholesterol (1.00%) Cholesterol (1.00%) Cholesterol (1.00%)
+ OOPL (0.16 %) + PPL (0.13%)
Body weight at 0 days (g) 2943 ±137 2868 ±172 2977 ±102
Body weight at 22 days (g) 3383 ±140∗ 3298 ±220∗ 3438 ± 148∗
Body weight increase (g) 440 ±113 430 ±130 461 ±144
Daily food consumption (g) 166.3 ±8.2 164.0 ±10.6 159.3 ±3.8
OOPL: Olive Oil Polar Lipids; PPL: Pomace Polar Lipids. Values are expressed as mean ± sd. ∗Signiﬁcant diﬀerence for P<. 05 within the same group, 22
days compared to 0 days, according to paired sample t-test; no statistical diﬀerence was detected in rabbit weight among groups both at 0 and 22 days.
Table 3: Lipid proﬁle of experimental groups.
Group A Group B Group C
Total cholesterol (mg/dL)
0 days 44 53.75 48
(36.50–50.50) (48.62–63.75) (41.38–50)
22 days 1348∗ 1421∗ 1054∗
(1199–1378) (782.6–1703) (775.0–1702)
HDL Cholesterol (mg/dL)
0 days 22.0 32.00 25.50
(19.50–24.50) (28.12–39.38) (21.12–27.62)
22 days 81.25∗ 77.50∗ 33.75∗,∗∗,#
(65.88–98.25) (58.25–89.50) (28.50–43.88)
LDL Cholesterol (mg/dL)
0 days 11.50 14.05 13.40
(8.650–19.30) (12.75–18.98) (10.98–17.35)
22 days 1195∗ 1332∗ 1003∗
(1106–1242) (696.1–1592) (730.0–1616)
Triglyceride (mg/dL)
0 days 81.5 75.5 79.25
(75.75–92.5) (72.50–96.25) (61.62–103.5)
22 days 220.5∗ 102.2 97.25∗∗
(110.6–285.9) (64.25–164.12) (82.75–146.9)
A: atherogenic diet, B: atherogenic diet with OOPL, and C: atherogenic diet with PPL. Values are expressed as median (25th percentile-75th percentile) (n =
6). ∗Signiﬁcant diﬀerence for P<. 05 within the same group, 22 days compared to 0 days, according to Wilcoxon test. ∗∗Signiﬁcant diﬀerence for P<. 05
compared to group A, according to Mann-Whitney U-test; #Signiﬁcant diﬀerence for P<. 05 compared to group B, according to Mann-Whitney U-test.8 Mediators of Inﬂammation
Table 4: Biochemical parameters of experimental groups.
Day Group A Group B Group C
Free PAF (pM)
0 15.7 7.26 5.84
(13.5–19.9) (6.73–14.4) (3.92–10.8)
22 36.9∗ 34.5∗ 21.8∗
(21.9–59.2) (18.7–48.4) (13.6–58.4)
Bound PAF (pM)
0 40.9 44.7 5.85
(33.0–48.5) (21.7–67.5) (2.69–21.6)
22 69.8∗ 59.6∗ 36.2∗,∗∗,#
(50.4–75.4) (42.5–80.2) (18.2–38.4)
EC50(nM)
0 31.5 22.5 24.5
(22.9–42.0) (14.8–41.2) (19.0–41.2)
22 12∗ 38.5∗,∗∗ 38∗,∗∗
(11.8–16.2) (20.5–67.5) (23.0–93.5)
PAF-AH activity [pmolPAF/(min ×μL PPP)]
0 124 224 181
(93.9–143) (180–247) (160–209)
22 262∗ 333∗ 288∗
(228–305) (284–399) (215–312)
A: atherogenic diet, B: atherogenic diet with OOPL, and C: atherogenic diet with PPL. Values are expressed as median (25th percentile-75th percentile) (n =
6). ∗Signiﬁcant diﬀerence for P<. 05 within the same group, compared to 0 days, according to Wilcoxon test. ∗Signiﬁcant diﬀerence for P<. 05 compared to
group A, according to Mann-Whitney U-test. #Signiﬁcant diﬀerence for P<. 05 compared to group B, according to Mann-Whitney U-test.
Table 5:Assessmentofearlyatherosclerosislesionsobservedinrab-
bit aortas.
Early atherosclerosis lesions evaluation
Groups Thickness (μm) Surface area (μm2) × 1000
A 489 ±49 1408 ±470
B 298 ±49∗ 835 ±234#
C 145 ±20∗,y 429 ±105#,y
Values of early atherosclerosis thickness and surface area occupied by foam
cells are expressed as mean ± sd. ∗Signiﬁcant diﬀerence for groups B or C
versus group A in atherosclerosis lesion thickness (P<. 05). #Signiﬁcant
diﬀerence for groups B or C versus group A in atherosclerosis lesion sur-
face area (P<. 05). ySigniﬁcant diﬀerence for group C versus group B in
atherosclerosis lesion thickness and surface area, respectively, (P<. 005).
Statistical analysis was based on independent sample t-test.
acid concentrations in PPL were signiﬁcantly lower than the
respective ones in OOPL. In addition, palmitoleic, stearic,
and linoleic fatty acids were only detected in OOPL. Palmitic
acid can be found in both OOPL and PPL, in approxi-
mately the same concentration. On the other hand, oleic and
α-linolenic acid concentrations in PPL are lower than the
ones in OOPL.
In a recent work [28], olive pomace lipid extract has been
puriﬁed on HPLC and the most potent PAF antagonist de-
rived from this procedure was characterized as glycerylether-
sn-2-acetyl glycolipid based on chemical determinations and
ESMS analysis. This active compound shares similar biolog-
ical activity, chromatographic behavior, and possibly struc-
ture to the one from olive oil polar lipids.
PPLinhibitionpotencyishigherthanthatofOOPLasin-
dicated by their IC50 values, which may be attributed to their
higher phenolic compound concentration whose antithrom-
boticactivityhasalreadybeenreported[21,45].PAFbinding
assays performed on rabbit platelets showed that both polar
lipid extracts are speciﬁc PAF receptor antagonists. In a simi-
lar way, PPL inhibition potency is higher than that of OOPL.
The aforementioned results indicate that these extracts exert
their inhibitory eﬀect on PAF actions by blocking PAF recep-
tor.
Enrichment of group B atherogenic diet with OOPL was
b a s e do np r evi o u ss t u d i e s[ 7, 27]. The amount of PPL, which
enriched group C atherogenic diet, was equivalent to that of
OOPL according to their IC50 values.
Conﬂicting results, concerning lipid proﬁle of rabbits fed
with atherogenic diet enriched in olive oil, exist in previous
studies[7,27].Ourﬁndingsarepartlyinaccordancewiththe
aforementioned ones. All these data indicate that lipid pro-
ﬁle may supply valuable information on the total condition
ofexperimentalmodels;however,itcannotprovideinforma-
tion on theatherosclerosis progression and blood vessel con-
dition.
Platelet aggregation ability as indicated by the EC50 val-
ues decreased in groups B and C while increased in group
A. No signiﬁcant diﬀerence was observed in the EC50 values
betweengroupsBandCafterfoodconsumption.Theseﬁnd-
ings suggest that PAF-antagonists present in OOPL and PPL
may be bioavailable in rabbit blood where they can exhibit
anti-PAF activity. Our ﬁndings are in accordance with those
of previous studies, in which EC50 values increased only in
rabbit groups that had consumed atherogenic diet enriched
either in olive oil or olive oil polar lipids [7, 27].
PAF levels have been shown to be elevated in vari-
ous inﬂammatory diseases, such as allergy, asthma, sepsis,
trauma, shock, acute pancreatitis, and diabetes. In turn, PAF
molecule can also promote oxidation, thus decisively con-
tributing to atherosclerosis initiation and progression, as has
been proposed by our group [2] .I nt h i ss t u d y ,l e v e l so fNektaria Tsantila et al. 9
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Figure 2: (a) Optic microphotographs (×200 for A and B; ×4 0 0f o rC )o fr e p r e s e n t a ti v ea t h e r o s c l e r o s is lesions of aortic wall sections stained
with haematoxylin and eosin. The arrows indicate the observed atherosclerosis lesions. A: atherogenic diet, B: atherogenic diet enriched with
OOPL, C: atherogenic diet enriched with PPL. (B) Thickness and surface area of early atherosclerosis lesions of the three experimental
groups, expressed as mean ± sd; ∗Signiﬁcant diﬀerence for groups B and C versus group A in atherosclerosis lesion thickness (P<. 05).
#Signiﬁcant diﬀerence for groups B and C versus group A in atherosclerosis lesion area (P<. 05). y,z Signiﬁcant diﬀerence for group C
versus group B in atherosclerosis lesion thickness and area respectively (P<. 005). Statistical analysis was based on independent sample
t-test.
PAF, both the one loosely bound to blood components (de-
ﬁ n e da s“ f r e e ” )a sw e l la st h eo n es t r o n g l yb o u n dt ob l o o d
components and cell-associated (deﬁned as “bound”), were
signiﬁcantly elevated in all three rabbit groups. It is well
known that a variety of cells such as platelets, monocytes,
macrophages, and so on biosynthesize PAF and PAF-like
lipids under atherogenic conditions, as well as the produced
PAFandPAF-likelipidsamplifycellactivation,whichinturn
further increases PAF levels [2, 15, 46, 47].
PAF-AH is the key enzyme to PAF degradation and its
activity signiﬁcantly increases during this study in all three
groups. The observed elevation may be attributed to the in-
creased PAF levels since inﬂammatory mediators in vivo in-
ducePAF-AHactivityandPAFstimulatesenzymeexpression
[48]. PAF-AH is suggested to serve either as a protective en-
zyme against acute inﬂammatory and oxidative factors, such
as PAF, or as a marker, concerning both disease progression
andseverity,inlongtermoxidativestressconditions[49,50].
In addition, overexpression of PAF-AH appears to induce
anti-atherogenic properties in animal model [15].
Rabbits belonging to groups B and C developed early
atherosclerosis lesions, at signiﬁcantly lower degree, com-
pared to group A. This is in accordance with our previous
study in which the antiatherosclerotic eﬀect of olive oil on
cholesterol fed rabbits was attributed to its polar lipid extract
(OOPL) [27]. Signiﬁcant diﬀerences were also noted in the
early atherosclerosis lesions of group C compared to those of
group B, indicating that PPL exhibit its anti-atherosclerotic
activity by blocking PAF receptor.
The speciﬁc antagonist of PAF, BN 52021, has been pre-
viously shown to exert beneﬁcial eﬀects against atherosclero-
sis development in rabbits [43]. In the present study, athero-
genic diet enriched in either OOPL or PPL, which are spe-
ciﬁc PAF antagonists, causes inhibition of early atheroscle-
rosis development in rabbits despite the fact that PAF levels
are elevated in their blood. These ﬁndings suggest that PAF-
antagonists from olive oil and olive pomace are able to slow
down the atherosclerotic process at least at its early stages by
inhibiting PAF binding and activity even in cases where PAF
levels are highly increased.
In conclusion, olive pomace contains PAF speciﬁc antag-
onists with similar bioactivities to those of olive oil. These
bioactive microconstituents inhibit both speciﬁc PAF bind-
i n ga n dP A Fa c t i v i t y( i nv i t r oa n di nv i v o ) ,c o n s e q u e n t l yi n -
hibiting early atherosclerosis development. The above data
reinforce the beneﬁcial eﬀect of food origin PAF antagonists
against atherosclerosis development and indicate a main role
of PAF in atherosclerosis.
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